Can you trust your animal study data?

The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers

(2013) P A Smink et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase II and Phase III attrition rates 2011–2012

(2013) John Arrowsmith et al.   NATURE REVIEWS DRUG DISCOVERY

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

(2013) PA Smink et al.   European Journal of Preventive Cardiology

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial

(2013) Hiddo J Lambers Heerspink et al.   European Journal of Preventive Cardiology

Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis

(2012) Gianluigi Savarese et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

(2010) Y. Miao et al.   DIABETOLOGIA

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET